Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00091949 · ClinicalTrials.gov registry record · Phase 3
Insulin Resistance Intervention After Stroke Trial
A Phase 3 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,876
- Enrollment target
NCT00091949 is a Phase 3 study that has completed, run by Yale University. The registered enrollment target is 3,876 participants.
The verdict
NCT00091949, a Phase 3 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,876 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if pioglitazone is effective in preventing future strokes or heart attacks among non-diabetic persons who have had a recent ischemic stroke.
Interventions
- DRUG placebo
- DRUG pioglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,876 participants |
| Start Date | 2005-02 |
| Est. Completion | 2015-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00091949
The ClinicalTrials.gov registry entry for NCT00091949 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,876 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00091949 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00091949 about?
NCT00091949 is a clinical study titled "Insulin Resistance Intervention After Stroke Trial". The purpose of this study is to determine if pioglitazone is effective in preventing future strokes or heart attacks among non-diabetic persons who have had a recent ischemic stroke.
What is the current status of trial NCT00091949?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,876 participants. The study started on 2005-02. Estimated completion is 2015-11.
What interventions are being tested in trial NCT00091949?
The interventions under investigation include: placebo (DRUG), pioglitazone (DRUG).
Who is sponsoring clinical trial NCT00091949?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.